aspsirna0694 details

''''
ASPsiRNA information siRNA Id:aspsirna0694
siRNA Name: G16mm
Mismatch information Wild siRNA (As strand 3'->5'):GUCCCCCUGGAUAGUCCUC
ASP-siRNA (As strand 3'->5'):GUCGCCCUGGAUAGUCCUG
Mismatch position in siRNA: G1U,G16C
Gene Information Gene Name Ataxin-3 (ATXN3)
Target Sequence (5'->3'):CAGCAGCAGCAGGGGGACCUAUCAGG
Wild allele (5'->3'):CAGGGGGACCUAUCAGGAG
Mutant allele (5'->3'):CAGCGGGACCUAUCAGGAA
Position of siRNA on target gene: NA
Respective Gene/Protein Resources GenBank Accession:NM_004993.5
Cytogenic location:14q32.12  
Chromosomal coordinates:14:92,524,895-92,572,964
UniProt ID:P54252
HUGO ID:7106
Reference SNp(RefSNP): rs12895357
Disease/Mutation information Target Mutation: c.892_894CAG(8_36) (p.Gln298_Gln305=)
Matation type/variant: Microsatellite
Mutation at gene level: NG_008198.2:g.40588_40590CAG(8_36)
Pathogenic status of mutation: Pathogenic
Disease:Spino Cerebellar Ataxia type-3 (SCA-3)
Clinical Resources ClinVar ID:3551
KEGG disease ID:H00063
OMIM ID: 109150
COSMIC: ATXN3
DECIPHER: ATXN3
GeneTests: ATXN3
ASP siRNA details Mutant allele (5'->3'): CAGCGGGACCUAUCAGGAA
ASP-siRNA (As strand 3'->5'):GUCGCCCUGGAUAGUCCUG
Percentage efficacy of ASP-siRNA for mutant allele:70
Wild allele (5'->3'): CAGGGGGACCUAUCAGGAG
ASP-siRNA (As strand 3'->5'):GUCGCCCUGGAUAGUCCUG
Percentage efficacy of ASP-siRNA for wild allele:38
Relative difference:32
Wild siRNA details Wild allele (5'->3'): CAGGGGGACCUAUCAGGAG
Wild siRNA (As strand 3'->5'):GUCCCCCUGGAUAGUCCUC
Percentage efficacy of wild siRNA for wild allele:60
Wild allele (5'->3'): CAGGGGGACCUAUCAGGAG
ASP-siRNA (As strand 3'->5'):GUCGCCCUGGAUAGUCCUG
Percentage efficacy of Wild sirna for mutant allele:15
Relative difference :45
General information Mismatch incorporated in siRNA/Target:siRNA
Cell-line used: Fibroblast
Experimental technique used: Western blot
Transfection method: Lipofectamine 2000
siRNA expression method: Metabion
Post-transfection duration: 72 hours
Concentration used:50nM
Reference:22397573
Delivery method:Transfection
Article title:An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases.
Authors:Fiszer A, Olejniczak M, Switonski PM, Wroblewska JP, Wisniewska-Kruk J, Mykowska A, Krzyzosiak WJ.
Journal Reference:BMC Mol Biol. 2012 Mar 7;13:6. doi: 10.1186/1471-2199-13-6.